Castleark Management LLC Invests $3.60 Million in Arcutis Biotherapeutics, Inc. $ARQT

Posted by Geri Gentry on Aug 27th, 2026

Castleark Management LLC acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) during the second quarter, HoldingsChannel reports. The firm acquired 137,420 shares of the company’s stock, valued at approximately $3,603,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. AQR Capital Management LLC raised its holdings in Arcutis Biotherapeutics by 21.4% during the first quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock worth $3,882,000 after purchasing an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Arcutis Biotherapeutics by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after buying an additional 2,063 shares during the last quarter. Creative Planning boosted its holdings in shares of Arcutis Biotherapeutics by 8.2% in the 2nd quarter. Creative Planning now owns 19,575 shares of the company’s stock valued at $274,000 after buying an additional 1,477 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Arcutis Biotherapeutics by 1.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 548,789 shares of the company’s stock valued at $7,694,000 after buying an additional 5,407 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of Arcutis Biotherapeutics by 4,562.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock valued at $157,000 after buying an additional 10,950 shares during the last quarter.

Insider Buying and Selling

In other news, insider Masaru Matsuda sold 1,230 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.12, for a total value of $32,127.60. Following the transaction, the insider owned 126,171 shares of the company’s stock, valued at approximately $3,295,586.52. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard G. Welgus sold 4,730 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $26.18, for a total value of $123,831.40. Following the sale, the director owned 36,475 shares of the company’s stock, valued at $954,915.50. This trade represents a 11.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 37,039 shares of company stock worth $954,813. 9.40% of the stock is currently owned by insiders.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ:ARQT opened at $25.14 on Thursday. Arcutis Biotherapeutics, Inc. has a one year low of $15.10 and a one year high of $31.77. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of 119.72 and a beta of 1.49. The company has a 50-day simple moving average of $26.72 and a 200-day simple moving average of $24.65. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The firm had revenue of $129.86 million for the quarter, compared to analyst estimates of $118.85 million. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. On average, analysts predict that Arcutis Biotherapeutics, Inc. will post 0.4 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ARQT. Morgan Stanley lifted their target price on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Wall Street Zen raised Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Guggenheim lifted their price target on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Needham & Company LLC lifted their price target on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 20th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Arcutis Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.57.

View Our Latest Report on ARQT

Arcutis Biotherapeutics Profile

(Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.